2抑制剂-话题@MedSci

#2抑制剂#

221篇内容 | 4060人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1995544, encodeId=3bf6199554464, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet：SGLT2抑制剂对II型糖尿病患者心血管及肾功能的影响研究, objectType=article, longId=153311, objectId=986d15331165, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=986d15331165, replyNumber=0, likeNumber=68, createdTime=2019-08-31, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=986d15331165, moduleTitle=Lancet：SGLT2抑制剂对II型糖尿病患者心血管及肾功能的影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=986d15331165)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995524, encodeId=36f3199552432, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Circulation：钠葡萄糖共转运体2抑制剂可改善2型糖尿病患者的心血管预后，但会增加下肢截肢风险, objectType=article, longId=135523, objectId=9830135523c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9830135523c0, replyNumber=0, likeNumber=61, createdTime=2018-10-26, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9830135523c0, moduleTitle=Circulation：钠葡萄糖共转运体2抑制剂可改善2型糖尿病患者的心血管预后，但会增加下肢截肢风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9830135523c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995546, encodeId=8b2619955466d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Xynomic制药从勃林格殷格翰获得mTORC1 / 2抑制剂的全球**经营权, objectType=article, longId=156446, objectId=8726156446da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8726156446da, replyNumber=0, likeNumber=76, createdTime=2019-05-20, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8726156446da, moduleTitle=Xynomic制药从勃林格殷格翰获得mTORC1 / 2抑制剂的全球**经营权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8726156446da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995535, encodeId=208f199553550, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JAMA Intern Med：SGLT-2抑制剂增加糖尿病患者下肢截肢风险, objectType=article, longId=146618, objectId=28f4146618a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28f4146618a8, replyNumber=0, likeNumber=103, createdTime=2019-02-13, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28f4146618a8, moduleTitle=JAMA Intern Med：SGLT-2抑制剂增加糖尿病患者下肢截肢风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28f4146618a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995533, encodeId=5f3d199553335, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：钠-葡萄糖共转运蛋白-2抑制剂与肢体骨折风险的关系, objectType=article, longId=145634, objectId=b6dd14563481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6dd14563481, replyNumber=0, likeNumber=65, createdTime=2018-08-20, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6dd14563481, moduleTitle=Diabetes Obes Metab：钠-葡萄糖共转运蛋白-2抑制剂与肢体骨折风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6dd14563481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995513, encodeId=c4f019955135b, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet Oncol：Prexasertib，细胞周期检查点激酶1和激酶2抑制剂，用于高级别浆液性卵巢癌的治疗效果和安全性评估。, objectType=article, longId=126820, objectId=fd5612682002, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5612682002, replyNumber=0, likeNumber=66, createdTime=2018-12-10, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5612682002, moduleTitle=Lancet Oncol：Prexasertib，细胞周期检查点激酶1和激酶2抑制剂，用于高级别浆液性卵巢癌的治疗效果和安全性评估。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5612682002)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995511, encodeId=72061995511b7, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Blood：Venetoclax，BCL-2抑制剂，用于idelalisib治疗中或治疗后的CLL患者的效果和安全性。, objectType=article, longId=125904, objectId=387a125904d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=387a125904d3, replyNumber=0, likeNumber=69, createdTime=2018-06-16, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=387a125904d3, moduleTitle=Blood：Venetoclax，BCL-2抑制剂，用于idelalisib治疗中或治疗后的CLL患者的效果和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=387a125904d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995527, encodeId=163a199552eca, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JACC：钠葡萄糖协同转运蛋白-2抑制剂可降低T2DM患者心血管发病风险, objectType=article, longId=140326, objectId=9d2b140326a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d2b140326a4, replyNumber=0, likeNumber=71, createdTime=2018-09-17, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d2b140326a4, moduleTitle=JACC：钠葡萄糖协同转运蛋白-2抑制剂可降低T2DM患者心血管发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d2b140326a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995523, encodeId=ba3a1995523b4, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Blood：JAK2抑制剂用于治疗骨髓增生性肿瘤（MFN）的效果和安全性评估, objectType=article, longId=135312, objectId=411e1353128b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=411e1353128b, replyNumber=0, likeNumber=82, createdTime=2018-06-15, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=411e1353128b, moduleTitle=Blood：JAK2抑制剂用于治疗骨髓增生性肿瘤（MFN）的效果和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=411e1353128b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995536, encodeId=970a199553698, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=FDA发出安全警告：2型糖尿病药物SGLT2抑制剂与严重的生殖器感染存在相关性, objectType=article, longId=147836, objectId=911e14e836f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=911e14e836f1, replyNumber=0, likeNumber=79, createdTime=2018-10-28, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=911e14e836f1, moduleTitle=FDA发出安全警告：2型糖尿病药物SGLT2抑制剂与严重的生殖器感染存在相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=911e14e836f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995525, encodeId=2933199552571, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Blood：JAK2抑制剂芦可替尼上市后的思考, objectType=article, longId=138017, objectId=3e8713801eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e8713801eaf, replyNumber=0, likeNumber=0, createdTime=2019-03-01, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e8713801eaf, moduleTitle=Blood：JAK2抑制剂芦可替尼上市后的思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e8713801eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995515, encodeId=77211995515ba, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Am Heart J：强效P2Y12抑制剂使ACS患者获益年龄不是问题, objectType=article, longId=127320, objectId=074b12e320a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=074b12e320a9, replyNumber=0, likeNumber=53, createdTime=2018-07-29, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=074b12e320a9, moduleTitle=Am Heart J：强效P2Y12抑制剂使ACS患者获益年龄不是问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=074b12e320a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995539, encodeId=8b5719955394b, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, objectType=article, longId=149631, objectId=33901496318e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33901496318e, replyNumber=0, likeNumber=66, createdTime=2019-08-17, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33901496318e, moduleTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33901496318e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995529, encodeId=a4d019955294d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=ESH2018丨SGLT-2抑制剂对于合并糖尿病的高血压患者之影响, objectType=article, longId=140961, objectId=878d1409614b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=878d1409614b, replyNumber=0, likeNumber=77, createdTime=2019-01-14, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=878d1409614b, moduleTitle=ESH2018丨SGLT-2抑制剂对于合并糖尿病的高血压患者之影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=878d1409614b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995510, encodeId=fa9219955101e, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Circulation：SGLT2抑制剂能降低心衰患者的死亡率吗？, objectType=article, longId=124757, objectId=8268124e577a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8268124e577a, replyNumber=0, likeNumber=79, createdTime=2018-10-03, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8268124e577a, moduleTitle=Circulation：SGLT2抑制剂能降低心衰患者的死亡率吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8268124e577a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995509, encodeId=45b31995509cc, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Circulation:转换血小板P2Y12抑制剂治疗的国际专家共识, objectType=article, longId=124756, objectId=eba3124e5682, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba3124e5682, replyNumber=0, likeNumber=63, createdTime=2018-08-07, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba3124e5682, moduleTitle=Circulation:转换血小板P2Y12抑制剂治疗的国际专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba3124e5682)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995519, encodeId=ef3b1995519c3, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=前景光明：BET和EZH2抑制剂治疗淋巴瘤, objectType=article, longId=131672, objectId=ff821316e2de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff821316e2de, replyNumber=0, likeNumber=69, createdTime=2019-02-08, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff821316e2de, moduleTitle=前景光明：BET和EZH2抑制剂治疗淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff821316e2de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Eur J Pharmacol：Bcl-2抑制剂ABT-737在过敏性鼻炎模型中的抗过敏性和抗炎症作用研究, objectType=article, longId=140910, objectId=2bdb14091076, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bdb14091076, replyNumber=0, likeNumber=94, createdTime=2018-12-21, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bdb14091076, moduleTitle=Eur J Pharmacol：Bcl-2抑制剂ABT-737在过敏性鼻炎模型中的抗过敏性和抗炎症作用研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bdb14091076)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995514, encodeId=5ecc1995514e9, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JAHA：2型糖尿病患者SGLT2抑制剂的心血管安全和长期非心血管疗效分析！, objectType=article, longId=127162, objectId=547a12e162f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=547a12e162f7, replyNumber=0, likeNumber=100, createdTime=2018-11-29, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=547a12e162f7, moduleTitle=JAHA：2型糖尿病患者SGLT2抑制剂的心血管安全和长期非心血管疗效分析！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=547a12e162f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995531, encodeId=6d961995531f8, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=NEJM：扎心了！治疗骨髓纤维化的JAK2抑制剂竟会导致淋巴瘤！, objectType=article, longId=141213, objectId=82cd14121391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82cd14121391, replyNumber=0, likeNumber=64, createdTime=2018-08-14, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82cd14121391, moduleTitle=NEJM：扎心了！治疗骨髓纤维化的JAK2抑制剂竟会导致淋巴瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82cd14121391)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2抑制剂

2020-05-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet：SGLT2抑制剂对II型糖尿病患者心血管及肾功能的影响研究

2019-08-31

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Circulation：钠葡萄糖共转运体2抑制剂可改善2型糖尿病患者的心血管预后，但会增加下肢截肢风险

2018-10-26

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Xynomic制药从勃林格殷格翰获得mTORC1 / 2抑制剂的全球**经营权

2019-05-20

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JAMA Intern Med：SGLT-2抑制剂增加糖尿病患者下肢截肢风险

2019-02-13

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：钠-葡萄糖共转运蛋白-2抑制剂与肢体骨折风险的关系

2018-08-20

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet Oncol：Prexasertib，细胞周期检查点激酶1和激酶2抑制剂，用于高级别浆液性卵巢癌的治疗效果和安全性评估。

2018-12-10

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Blood：Venetoclax，BCL-2抑制剂，用于idelalisib治疗中或治疗后的CLL患者的效果和安全性。

2018-06-16

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JACC：钠葡萄糖协同转运蛋白-2抑制剂可降低T2DM患者心血管发病风险

2018-09-17

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Blood：JAK2抑制剂用于治疗骨髓增生性肿瘤（MFN）的效果和安全性评估

2018-06-15

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

FDA发出安全警告：2型糖尿病药物SGLT2抑制剂与严重的生殖器感染存在相关性

2018-10-28

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Blood：JAK2抑制剂芦可替尼上市后的思考

2019-03-01

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Am Heart J：强效P2Y12抑制剂使ACS患者获益年龄不是问题

2018-07-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率

2019-08-17

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

ESH2018丨SGLT-2抑制剂对于合并糖尿病的高血压患者之影响

2019-01-14

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Circulation：SGLT2抑制剂能降低心衰患者的死亡率吗？

2018-10-03

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Circulation:转换血小板P2Y12抑制剂治疗的国际专家共识

2018-08-07

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

前景光明：BET和EZH2抑制剂治疗淋巴瘤

2019-02-08

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Eur J Pharmacol：Bcl-2抑制剂ABT-737在过敏性鼻炎模型中的抗过敏性和抗炎症作用研究

2018-12-21

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JAHA：2型糖尿病患者SGLT2抑制剂的心血管安全和长期非心血管疗效分析！

2018-11-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

NEJM：扎心了！治疗骨髓纤维化的JAK2抑制剂竟会导致淋巴瘤！

2018-08-14

科室
- - 订阅+
  - 更多科室
工具
服务